Dergiler / Turkish Journal of Gastroenterology / 2017 / Cilt: 28 - Sayı: 2

Hypergammaglobulinemia is a marker of extraintestinal manifestations in pediatric inflammatory bowel disease

Sayfa
131–134
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Hypergammaglobulinemia is a marker of extraintestinal manifestations in pediatric inflammatory bowel disease and may assist in distinguishing arthritis from arthralgia.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: The significance of hypergammaglobulinemia as a phenotypic feature of inflammatory bowel disease is unknown.
📊
Temel Bulgular & Veri:Materials and Methods: The medical records of 296 pediatric onset inflammatory bowel disease patients who were evaluated from 2002 to 2015 were retrospectively reviewed.
💡
Sonuç & Katkı:Conclusion: Hypergammaglobulinemia is a marker of extraintestinal manifestations in pediatric inflammatory bowel disease and may assist in distinguishing arthritis from arthralgia.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2002 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: The significance of hypergammaglobulinemia as a phenotypic feature of inflammatory bowel disease is unknown. Thus, we aimed to analyze the magnitude and significance of hypergammaglobulinemia in newly diagnosed pediatric inflammatory bowel disease patients. Materials and Methods: The medical records of 296 pediatric onset inflammatory bowel disease patients who were evaluated from 2002 to 2015 were retrospectively reviewed. Patients with recorded immunoglobulin G (IgG) levels were categorized as either normal or high IgG levels at diagnosis. Baseline characteristics included age at onset, sex, severity indices, laboratory data, extraintestinal manifestations, endoscopic findings, and anthropometric measurements.Results: Of 184 subjects [mean age, 13.2±2.8 years; 105 (60%) males] with recorded IgG levels, 129 (70%) had Crohn disease, 46 (25%) had ulcerative colitis, and 9 (5%) had unclassified inflammatory bowel disease. Overall, 46 patients (25%) had hypergammaglobulinemia, including 30 (23%) with Crohn disease, 14 (30%) with ulcerative colitis, and 2 (22%) with unclassified disease. Hypergammaglobulinemia was associated with the female sex (55% vs. 35%; p=0.03) and extraintestinal manifestations (70% vs. 10%; p<0.0001), including arthritis, skin disorders, and primary sclerosing cholangitis but not with arthralgia. It was also associated with corticosteroid induction (68% vs. 45%; p=0.02) and maintenance with an immunomodulator (61% vs. 21%; p=0.0001) after diagnosis. In ulcerative colitis patients, hypergammaglobulinemia was associated with a high pancolitis prevalence (p=0.002). Conclusion: Hypergammaglobulinemia is a marker of extraintestinal manifestations in pediatric inflammatory bowel disease and may assist in distinguishing arthritis from arthralgia.

🔖

Bu Makaleye Atıf Yap

MATAR, M., RİNAWİ, F., SHAMİR, R., ASSA, A. (2017). Hypergammaglobulinemia is a marker of extraintestinal manifestations in pediatric inflammatory bowel disease. Turkish Journal of Gastroenterology, Cilt: 28 - Sayı: 2, 131–134. https://ajindex.com/articles/410222

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (4)

  1. Dispenzieri A, Gertz MA, Therneau TM, Kyle RA. Retrospective co- hort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 2001; 76: 476-87. [CrossRef] Pizzo PA, Lovejoy FH Jr, Smith DH. Prolonged fever in children: review of 100 cases. Pediatrics 1975; 55: 468-73.
  2. Liberal R, Vergani D, Mieli-Vergani G. Update on Autoimmune Hepatitis. J Clin Transl Hepatol 2015; 3: 42-52. [CrossRef] IBD Working Group of the European Society for Paediatric Gastro- enterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7. [CrossRef] Levine A, Koletzko S, Turner D, et al. European Society of Pediatric Gastroenterology, and Nutrition. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014; 58: 795-806.
  3. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314-21. [CrossRef] Lo MS, Zurakowski D, Son MB, Sundel RP. Hypergammaglobu- linemia in the pediatric population as a marker for underlying autoimmune disease: a retrospective cohort study. Pediatr Rheu- matol Online J 2013; 11: 42. [CrossRef] Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 307-27. [CrossRef] Harbord M, Annese V, Vavricka SR, et al; European Crohn's and Colitis Organisation. The First European Evidence-based Consen- sus on Extra-intestinal Manifestations in Inflammatory Bowel Dis- ease. J Crohns Colitis 2016; 10: 239-54. [CrossRef] Aloi M, Cucchiara S. Extradigestive manifestations of IBD in pedi- atrics. Eur Rev Med Pharmacol Sci 2009; 13(Suppl 1): 23-32.
  4. Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifesta- tions of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 2010; 51: 140-5. [CrossRef] McQueen F. A B cell explanation for autoimmune disease: the for- bidden clone returns. Postgrad Med J 2012; 88: 226-33. [CrossRef] Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythe- matosus. Arthritis Res Ther 2011; 13: 228. [CrossRef] Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymor- phisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and